Navigation Links
Johns Hopkins and Makerere University to collaborate on African health education initiative
Date:12/1/2008

The Johns Hopkins University has received a $4.97 million grant from the Bill & Melinda Gates Foundation to undertake the initial phase of a unique program aimed at improving health outcomes in Uganda and East Africa, in coordination with the Johns Hopkins Center for Global Health, and the Makerere University College of Health Sciences in Kampala, Uganda. As part of the initiative, the faculties of medicine, nursing, and public health at both schools will develop an institution-building relationship to further extend the educational capacity of Makerere University, Uganda's largest university.

The funding will support a two-year needs assessment and strategic planning process to define the goals and objectives of a 10-year institution-building initiative between the two universities. The project will be led by David Peters, MD, DrPH, an associate professor in the Department of International Health at the Johns Hopkins Bloomberg School of Public Health, and George Pariyo, MBChB, PhD, head of the Department of Health Policy, Planning, and Management at the Makerere University School of Public Health.

The first phase of this project will focus on aligning Makerere's educational and research capacity with Uganda's national health goals and priorities, as well as identifying strategies to ensure long-term sustainability of the university's efforts to address evolving health priorities and health manpower needs.

The project will also develop and test effective teaching, research, and practice strategies for Makerere and its partners. Existing strategies for placement of health practitioners and delivery of health services will be revised, and new strategies for life-saving services will be evaluated, with a focus on translating research into policy implementation.

"We see this project as a major stepping stone," Peters stated, "to ensure that Makerere will be the hub for capacity building and influencing the health sector to improv
'/>"/>

Contact: Tim Parsons
410-955-7619
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Johnson & Johnson Begins Tender Offer to Acquire Omrix
2. UC San Diego announces collaboration with Johnson & Johnson Pharmaceutical Research & Development
3. Robert Wood Johnson Foundation Announces Grant Recipients for $18 Million Dollar Initiative to Prevent Intimate Partner Violence
4. Former Miss America Nicole Johnson Takes Action for Type 1 Diabetes Research
5. JOHNSONS(R) and March of Dimes(R) Launch Prevent Prematurity Campaign
6. Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc.
7. Johnson & Johnson Reports 2008 Third-Quarter Results:
8. NCPA Endorses U.S. Senator Tim Johnson for Re-Election
9. Texas Health Resources Receives Grant From Robert Wood Johnson Foundation to Support Prevention of Family Violence
10. Johnson & Johnson Share Exchange Offer
11. Johns Hopkins researchers suppress hunger hormone

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)..., BEDFORD, Mass., Nov. 27 /PRNewswire-FirstCall/...ny"), a supplier of precision technology products ... annual meeting of the Company,s shareholders has ...me and location of the meeting will be announced i...y received a requisition notice from Stephen Bersh...
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 ...ed that Blair Lambert, CFO/COO, will present at th...held at the May Fair Hotel in London, England, on ..., To listen to a live broadcast of The Gymboree ...se log on to www.gymboree.com, click on "Our Compa...
(Date:11/27/2009)... XenaCare Holdings has announced t...tis Foundation, one of the largest nonprofit organ...c health education. , Del...e Holdings, Inc. (OTCBB: XCHO), a company speciali...onsumer healthcare products, has announced today t...
(Date:11/27/2009)... Voyant Health™ announced to...has licensed its TraumaCad Enterprise orthopedic t...ow solution. , (PRWEB) No...today that Spectrum Health (Grand Rapids, Michigan... templating solution and its TraumaCad Extend work...
(Date:11/26/2009)..., NEW YORK, Nov. 27 With cold and... to employ good practices to control the spread of...e proactive not only to keep ourselves healthy, bu...id Eileen Finerty, RN, MS, CIC (certified in infec...rol and occupational health at Hospital for Specia...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
...ative Legume Research (CILR) have screened legumes...il bacteria// in their roots, for biological activ...ch could potentially prevent the formation of a bl...application for compounds to treat cancer. ...
...th breast cancer in England has started a protest ...rug treatment// at a hospital. Local health boards...like the Shropshire Primary Care Trust. The patien...at breast cancer patients from Wales are getting t...
...ually snoring parents are also at an increased ris...esearchers have also found that children with atop... for chronic snoring. Sleep-disordered breat...ow becomes obstructed, the throat and tongue vibra...
... Inc., a U.S. biopharmaceutical company, Cesario V... at the Medical College of Georgia in Augusta and ...s into the brains of rats that had suffered stroke...American Academy of Neurology annual meeting, in S...
...hropshire and parts of Wales. Breast cancer patien... drug Herceptin but Welsh women get it for free. /...re Trust in Shropshire refused to pay for Hercepti... for the drug for women living in Wales even if th...
...tage, localized breast cancer new patterns and ris...d that may influence how patients are treated. // ...rom 1988 to 2002 was reviewed by Cancer Research C...t DCIS and LCIS develop. The authors noted t...
Other Medicine News:Health News:Compounds In Legume May Be Helpful In Treating Cancer 2Health News:Cancer Patients Protest For Free Drug Treatment 2Health News:Snoring Runs in the Family 2Health News:Neurological Damage Can Be Reduced By Stem Cell Transplants 2Health News:Free Herceptin Treatment for Those Who Live Over the Welsh Border 2
(Date:11/25/2009)...re/ -- Reportlinker.com announces that a new marke..., Mammography Equipment - A Global Market Per...4330/Mammography-Equipment---A-Global-Market-Persp...er in industrialized as well as developing nations...ammography market. Globally, escalating awareness ...
(Date:11/25/2009)...RNewswire/ -- Cempra Pharmaceuticals Inc. today an...chief executive officer, will present at the Piper...0 a.m. EST, December 1, 2009, at The New York Pala...vide an overview of the company,s two leading anti...-resistant pathogens including MRSA. ,, About ...
(Date:11/25/2009)...Newswire/ -- ChemoCentryx, Inc., announced today...s PROTECT-1 (the Prospective Randomized Oral Thera...t-EN(TM) (CCX282-B) in patients with moderate-to-s...cy with a favorable safety and tolerability profil...ficacy in the reduction of disease severity as def...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 1Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 2Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 3SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 10712 1SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 10712 2Study Links Yo Yo Dieting to Addiction 61264 1Study Links Yo Yo Dieting to Addiction 61264 2Study Links Yo Yo Dieting to Addiction 61264 3
...E: SHP,Nasdaq: SHPGY), the global specialty biopha...ientific meeting findings from analyses of pivotal...onist. This compound is an,investigational once-da...reatment of the symptoms of Attention Deficit Hype...hat INTUNIV showed significant efficacy in,reducin...
... Expected at ASCO in June -, SOUTH SAN FRANCISCO,...daq: PARD ), a biopharmaceutical company focused,... patient enrollment in,its Phase 2 clinical trial ... the first-line treatment of metastatic colorectal...cted in the second half of 2008. Picoplatin,the Co...
Other Medicine Technology:Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 2Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 3Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 4Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 5Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 6Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 2Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 3Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 4
HbA1c/Hb Calibrator Series
STA HEPANORM H
STA HEPARIN CONTROL
STA COAG CONTROL N + ABN
Medicine Products: